Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 20
1966 25
1967 28
1968 24
1969 41
1970 39
1971 25
1972 36
1973 39
1974 39
1975 32
1976 23
1977 22
1978 37
1979 35
1980 33
1981 35
1982 31
1983 42
1984 47
1985 52
1986 33
1987 69
1988 49
1989 50
1990 49
1991 52
1992 54
1993 57
1994 91
1995 66
1996 123
1997 82
1998 115
1999 166
2000 236
2001 272
2002 279
2003 310
2004 359
2005 406
2006 377
2007 375
2008 467
2009 525
2010 580
2011 641
2012 696
2013 707
2014 801
2015 788
2016 809
2017 764
2018 762
2019 762
2020 981
2021 977
2022 932
2023 798
2024 812
2025 413

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,643 results

Results by year

Filters applied: . Clear all
Page 1
How patients with multiple sclerosis acquire disability.
Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA. Lublin FD, et al. Brain. 2022 Sep 14;145(9):3147-3161. doi: 10.1093/brain/awac016. Brain. 2022. PMID: 35104840 Free PMC article.
Ageing and multiple sclerosis.
Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJM, Segal BM. Graves JS, et al. Lancet Neurol. 2023 Jan;22(1):66-77. doi: 10.1016/S1474-4422(22)00184-3. Epub 2022 Oct 7. Lancet Neurol. 2023. PMID: 36216015 Review.
Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN. Lamb YN. Drugs. 2022 Feb;82(3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22. Drugs. 2022. PMID: 35192158 Free PMC article. Review.
Treatment of Multiple Sclerosis.
Cross A, Riley C. Cross A, et al. Continuum (Minneap Minn). 2022 Aug 1;28(4):1025-1051. doi: 10.1212/CON.0000000000001170. Continuum (Minneap Minn). 2022. PMID: 35938656 Review.
Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Chisari CG, et al. J Neurol. 2022 Jan;269(1):159-183. doi: 10.1007/s00415-020-10362-z. Epub 2021 Jan 8. J Neurol. 2022. PMID: 33416999 Free PMC article. Review.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE. Bar-Or A, et al. EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22. EBioMedicine. 2023. PMID: 37354600 Free PMC article. Clinical Trial.
15,643 results
You have reached the last available page of results. Please see the User Guide for more information.